Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 3Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Pancreatic Neoplasms 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Fludzoparib" and Anti-angiogenic 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Breast Cancer Metastatic 1

Interventions

Cyclophosphamide 149Docetaxel 139Paclitaxel 127Trastuzumab 120Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × fluzoparib × Clear all
NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Fudan University

Phase 3 Recruiting
766 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡